# Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

> **NCT01104662** · PHASE4 · TERMINATED · sponsor: **Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 92 (actual)

## Conditions studied

- Complicated Skin and Skin Structure Infections
- S. Aureus Bacteremia
- Renal Impairment

## Interventions

- **DRUG:** Vancomycin
- **DRUG:** Daptomycin
- **DRUG:** Semi-Synthetic Penicillin

## Key facts

- **NCT ID:** NCT01104662
- **Lead sponsor:** Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04-19
- **Primary completion:** 2012-06-12
- **Final completion:** 2012-06-12
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop.
- **Last updated:** 2018-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01104662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01104662, "Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01104662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*